7 recruiting, 4 completed, 3 not yet recruiting. 4 Phase 3, 3 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 3, Completed 1 |
| Phase 2 | 3 | Not yet recruiting 2, Recruiting 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Thyroid Eye Disease, TED: new trials by email Literature Review of Thyroid Eye Disease, TED trials Research Report on Thyroid Eye Disease, TED
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status - Graves' Orbitopathy, Thyroid Eye Disease, TED | Recruiting | University of Copenhagen | 430 | 2026-10-16 | 2026-10-27 | |
| Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study MHB018A, MHB018A placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 84 | 2026-09-28 | 2026-10-14 |
| Treatment of Chronic Thyroid Eye Disease With MHB018A MHB018A injection, MHB018A injection Placebo - Thyroid Eye Disease, TED | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 135 | 2026-09-24 | 2026-10-14 |
| Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) linsitinib, Placebo - Thyroid Eye Disease, TED, Graves Orbitopathy | Phase 3 | Recruiting | Sling Therapeutics, Inc. | 130 | 2026-08-04 | 2026-10-20 |
| Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-08-01 | 2026-05-19 |
| A Clinical Study of Cizutamig in Thyroid Eye Disease Cizutamig will be dosed according to the protocol. - Thyroid Eye Disease, TED | Phase 1 | Recruiting | Candid Therapeutics | 38 | 2026-05-08 | 2026-09-01 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
| Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease Atorvastatin (Lipitor), Vitamin D - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Not applicable | Recruiting | Taipei Veterans General Hospital, Taiwan | 120 | 2026-02-24 | 2026-04-30 |
| Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease Teprotumumab Injection [Tepezza] - Thyroid Eye Disease, Thyroid Eye Disease, TED | Phase 4 | Not yet recruiting | Sheba Medical Center | 40 | 2026-01-01 | 2025-12-30 |
| Psychological Burden of Thyroid Eye Disease focus groups and individual interviews as well as filling out questionnaires - Thyroid Eye Disease, TED | Completed | Thomas Jefferson University | 20 | 2025-01-01 | 2026-03-02 | |
| Triamcinolone Acetonide Injection for Upper Eyelid Retraction in Thyroid Eye Disease Triamcinolone Acetonide - Thyroid Eye Disease, TED | Not applicable | Completed | Instituto de Oftalmología Fundación Conde de Valenciana | 29 | 2024-06-20 | 2026-10-16 |
| A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease IBI311 - Thyroid Eye Disease, TED | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 91 | 2023-10-20 | 2026-05-01 |
| Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment The patients with active or inactive TED - Thyroid Eye Disease, TED | Completed | Tianjin Eye Hospital | 58 | 2020-01-01 | 2025-07-09 |
Graves Ophthalmopathy (14) · Graves Disease (3) · Autoimmune Diseases (1) · Hashimoto Disease (1) · Inflammation (1) · Optic Nerve Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Endocrine System Diseases (14) · Exophthalmos (14) · Eye Diseases (14) · Eye Diseases, Hereditary (14) · Genetic Diseases, Inborn (14) · Goiter (14) · Hyperthyroidism (14) · Immune System Diseases (14) · Orbital Diseases (14) · Thyroid Diseases (14) · Autoimmune Diseases (13) · Graves Disease (11) · Cranial Nerve Diseases (1) · Nervous System Diseases (1)
Atorvastatin (2) · teprotumumab (2) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · Exercise (1) · Focus Groups (1) · Hematologic Tests (1) · Lipids (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Triamcinolone Acetonide (1) · Vitamin D (1) · tofacitinib (1)
Minghui Pharmaceutical (Hangzhou) Ltd (2) · Candid Therapeutics (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Instituto de Oftalmología Fundación Conde de Valenciana (1) · Region Skane (1) · Sheba Medical Center (1) · Sling Therapeutics, Inc. (1) · Sun Yat-sen University (1) · Taipei Veterans General Hospital, Taiwan (1) · The First Affiliated Hospital of Xiamen University (1) · Thomas Jefferson University (1) · Tianjin Eye Hospital (1) · University of Copenhagen (1)
China (5) · United States (4) · Denmark (1) · Mexico (1) · Sweden (1) · Taiwan (1)
Birte Nygaard, M.D., Ph.D. (1) · Chin-Sung Kuo, MD, PhD (1) · Fangsen Xiao, MD (1) · Floriana Bytyqi, M.D (1) · Jens Pedersen, M.D., Ph.D. (1) · Tereza Planck (1)
2023 (1)